To Evaluate the Safety and Efficacy of Human CD19 Targeted DASH CAR-T Cells Injection for Subjects With R/R B-ALL
Status:
Recruiting
Trial end date:
2025-09-30
Target enrollment:
Participant gender:
Summary
This study is a single-arm, open-label, dose-escalation trial to explore the safety,
tolerability and pharmacokinetic/pharmacodynamics characteristics of human CD19 targeted DASH
CAR-T Cells injection, and to preliminarily observe the efficacy of the trial drug in
patients with relapsed/refractory B-cell acute lymphoblastic leukemia.